我国上市专利药品可获得性实证研究  

Empirical Study on the Availability of Patented Drugs in China

作　　者：李孟林 徐伟[1] 杜雯雯[1] 陈明艳 孟令萱 LI Meng-lin;XU Wei;DU Wen-wen;CHEN Ming-yan;MENG Ling-xuan(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing Jiangsu 211198,China)

机构地区：[1]中国药科大学国际医药商学院

出　　处：《卫生经济研究》2019年第12期59-61,共3页

摘　　要：实证分析我国上市专利药品,特别是其中的重大疾病防治用药、公共卫生用药、临床急需特效药在样本医疗机构中的配备情况及可获得性。整体来看,专利药品在样本医疗机构中的配备品种数呈逐年上升趋势,且占当年我国已上市专利药品比重维持在40%左右;但可获得性较低,仅为5.45%~8.03%,其中,临床急需特效药可获得性最低。对此,需要从研发、使用、医保支付等环节,促进专科药品的研发生产和合理使用。This paper analyzed the listing of patented drugs in China,especially the availability of major disease prevention and treatment drugs,public health drugs,and clinically needed special drugs in sample medical institutions.On the whole,the number of patented drugs in the sample medical institutions has been increasing year by year,and the proportion of patented drugs in China has remained at around 40%.However,the availability is low,only 5.45%to 8.03%.Among them,the clinically needed special drugs has the lowest availability.In this regard,it is necessary to promote the research and development,production and rational use of specialty medicines from the aspects of research and development,use,and medical insurance payment.

关 键 词：专利药品 可获得性 重大疾病防治用药 公共卫生用药 临床急需特效药 

分 类 号：R197[医药卫生—卫生事业管理]